I am worried. B.1.351 (501Y.V2) evades part of the vaccines. In addition, in south africa previous infection DID NOT prevent infection with B.1.135 in the Novavax study. On addition, spreading of this one in S. Africa and P1 in Amazonia also suggests immjne evasion, given the high frequency of infections in the first wave. Assuming that B1.351 is inherently spreading faster than current variants (which i think, based on ACE2 affinity) but maybe not more efficient than B.1.1.7 the scenario we may see in the near future is the following: B1.1.7 takes over until around Q4 when vaccination is adequate, meaning that cases will rise until the end of summer. After that B1.351 takes over, because in spreading it may be not more efficient than B.1.1.7, but it will evade vaccine and B.1.1.7 immunity. Maybe severity may be lower in that winter 21-22 wave, but even that may not be the case.
Unfortunately this now seems a realistic projection.
Unfortunately this now seems a realistic projection.
Comment